Changes in membrane glycoproteins of circulating platelets after coronary stent implantation.

M. Gawaz, F. J. Neumann, I. Ott, A. May, S. Rüdiger, A. Schömig

1. Medizinische Klinik der Technischen Universität München, Germany.

OBJECTIVES: To evaluate platelet function in patients with coronary stents. DESIGN: A non-randomised control trial in 30 patients who had immediate implantation of Palmaz-Schatz coronary stents because of a suboptimal angioplasty result. All patients received a standardised anticoagulation regimen including intravenous heparin (activated partial thromboplastin time (APTT) 80 to 120 s), oral vitamin K antagonist (target international normalised ratio (INR) of 3.5), and 100 mg aspirin twice daily. Platelet surface expression of glycoprotein IIb-IIIa, activated fibrinogen receptor, and P-selectin as well as binding of von Willebrand factor and fibrinogen were determined by flow cytometry in peripheral venous blood samples collected before the intervention and then daily for 4 days after it. The results were compared with those in 30 patients undergoing elective coronary balloon angioplasty. SETTING: University hospital. RESULTS: After coronary stenting surface expression of the activated fibrinogen receptor significantly increased, peaking at day 2 (P < 0.001). Similar results were found for von Willebrand factor binding and P-selectin surface expression, with a maximum at day 2 to 4 after stenting (von Willebrand factor, P < 0.001; P-selectin, P < 0.001). The changes in platelet membrane glycoproteins coincided with a significant drop in peripheral platelet count after stent placement (P < 0.01). No significant change in fibrinogen receptor activity, von Willebrand factor binding, P-selectin surface expression, or platelet count was seen in the control group. CONCLUSIONS: The present study shows that current anticoagulation treatment is inefficient in suppressing platelet activation in patients with coronary stents and, therefore, might not be the best treatment for reducing the incidence of subacute stent thrombosis.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Kochiadakis, G. E., Marketou, M. E., Panutsopulos, D., Arfanakis, D. A., Skalidis, E. I., Igoumenidis, N. E., Hamilos, M. I., Sourvinos, G., Chlouverakis, G., Spandidos, D., Vardas, P. E. (2008). Vascular endothelial growth factor protein levels and gene expression in peripheral monocytes after stenting: a randomized comparative study of sirolimus: eluting and bare metal stents. Eur Heart J 29: 733-740 [Abstract] [Full Text]  
• Boos, C. J., Balakrishnan, B., Jessani, S., Blann, A. D., Lip, G. Y. H. (2007). Effects of Percutaneous Coronary Intervention on Peripheral Venous Blood Circulating Endothelial Cells and Plasma Indices of Endothelial Damage/Dysfunction. Chest 132: 1920-1926 [Abstract] [Full Text]  
• Stone, G. W., Aronow, H. D. (2006). Long-term Care After Percutaneous Coronary Intervention: Focus on the Role of Antiplatelet Therapy. Mayo Clin Proc. 81: 641-652 [Abstract] [Full Text]  
• Day, J R S, Malik, I S, Weerasinghe, A, Poullis, M, Nadra, I, Haskard, D O, Taylor, K M, Landis, R C (2004). Distinct yet complementary mechanisms of heparin and glycoprotein IIb/IIIa inhibitors on platelet activation and aggregation: implications for restenosis during percutaneous coronary intervention. Heart 90: 794-799 [Abstract] [Full Text]  
• Kopp, C. W., Steiner, S., Nasel, C., Seidinger, D., Mlekusch, I., Lang, W., Bartok, A., Ahmadi, R., Minar, E. (2003). Abciximab Reduces Monocyte Tissue Factor in Carotid Angioplasty and Stenting. Stroke 34: 2560-2567 [Abstract] [Full Text]  
• Kapadia, S. R., Bajzer, C. T., Ziada, K. M., Bhatt, D. L., Wazni, O. M., Silver, M. J., Beven, E. G., Ouriel, K., Yadav, J. S. (2001). Initial Experience of Platelet Glycoprotein IIb/IIIa Inhibition With Abciximab During Carotid Stenting: A Safe and Effective Adjunctive Therapy. Stroke 32: 2328-2332 [Abstract] [Full Text]  
• Kastrati, A., Koch, W., Gawaz, M., Mehilli, J., Bottiger, C., Schomig, K., von Beckerath, N., Schomig, A. (2000). PlA polymorphism of glycoprotein IIIa and risk of adverse events after coronary stent placement. J Am Coll Cardiol 36: 84-89 [Abstract] [Full Text]  
• von Beckerath, N., Koch, W., Mehilli, J., Bottiger, C., Schomig, A., Kastrati, A. (2000). Glycoprotein Ia gene C807T polymorphism and risk for major adverse cardiac events within the first 30 days after coronary artery stenting. Blood 95: 3297-3301 [Abstract] [Full Text]  
• Quinn, M. J., Fitzgerald, D. J. (1999). Ticlopidine and Clopidogrel. Circulation 100: 1667-1672 [Abstract] [Full Text]  
• Kastrati, A., Schomig, A., Seyfarth, M., Koch, W., Elezi, S., Bottiger, C., Mehilli, J., Schomig, K., von Beckerath, N. (1999). PlA Polymorphism of Platelet Glycoprotein IIIa and Risk of Restenosis After Coronary Stent Placement. Circulation 99: 1005-1010 [Abstract] [Full Text]  
• Gawaz, M., Neumann, F.-J., Schomig, A. (1999). Evaluation of Platelet Membrane Glycoproteins in Coronary Artery Disease : Consequences for Diagnosis and Therapy. Circulation 99 : e1-e11 [Full Text]  
• Steinhubl, S. R., Lauer, M. S., Mukherjee, D. P., Moliterno, D. J., Lincoff, A. M., Ellis, S. G., Topol, E. J. (1998). The duration of pretreatment with ticlopidine prior to stenting is associated with the risk of procedure-related non-Q-wave myocardial infarctions. J Am Coll Cardiol 32: 1366-1370 [Abstract] [Full Text]